Genetic Price To Sales Ratio from 2010 to 2024

GENE Stock  USD 0.77  0.00  0.00%   
Genetic Technologies' Price To Sales Ratio is decreasing over the years with slightly volatile fluctuation. Price To Sales Ratio is expected to dwindle to 1.33. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Genetic Technologies' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
1.39724698
Current Value
1.33
Quarterly Volatility
12.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Genetic Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genetic Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 508.1 K, Interest Expense of 83.6 K or Total Revenue of 5.3 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0 or PTB Ratio of 5.56. Genetic financial statements analysis is a perfect complement when working with Genetic Technologies Valuation or Volatility modules.
  
Check out the analysis of Genetic Technologies Correlation against competitors.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

Latest Genetic Technologies' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Genetic Technologies over the last few years. Price to Sales Ratio is figured by comparing Genetic Technologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Genetic Technologies sales, a figure that is much harder to manipulate than other Genetic Technologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Genetic Technologies' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genetic Technologies' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.38 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Genetic Price To Sales Ratio Regression Statistics

Arithmetic Mean3,491
Geometric Mean48.48
Coefficient Of Variation362.25
Mean Deviation6,093
Median25.55
Standard Deviation12,646
Sample Variance159.9M
Range49.2K
R-Value(0.44)
Mean Square Error138.4M
R-Squared0.20
Significance0.1
Slope(1,254)
Total Sum of Squares2.2B

Genetic Price To Sales Ratio History

2024 1.33
2023 1.4
2022 1.87
2021 3.89
2020 541.79
2019 23.69
2018 692.83

About Genetic Technologies Financial Statements

Genetic Technologies stakeholders use historical fundamental indicators, such as Genetic Technologies' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Genetic Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genetic Technologies' assets and liabilities are reflected in the revenues and expenses on Genetic Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genetic Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 1.40  1.33 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:
Check out the analysis of Genetic Technologies Correlation against competitors.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.02)
Revenue Per Share
2.19
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.63)
Return On Equity
(1.85)
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.